Alpharadin

Type: Product

Name: Alpharadin

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Bayer Prostate Cancer Drug Gains FDA Approval

Bayer HealthCare said yesterday it is weeks away from joining Algeta in bringing to the U.S. market their advanced prostate cancer drug Xofigo® (radium Ra 223 dichloride) following approval yesterday by FDA.The second new prostate cancer treatment approved ... [Published Genetic Engineering News - May 16 2013]

Entities: Prostate Cancer, FDA Food & Drug Administration, Bayer AG, bone metastases

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Nuclear Medicine/Radiopharmaceuticals Market - Global Trends & Forecast to 2017

Research and Markets (http://www.researchandmarkets.com/research/hr5gfs/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications ... [Published Individual.com - May 08 2013]

Entities: radiopharmaceutical, Nuclear Medicine, Market, Isotopes, Radioisotope

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Recent Study: North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017

(live-PR.com) - North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast ... [Published Live-PR.com - May 02 2013]

Entities: radiopharmaceutical, Isotopes, Market, Radioisotope

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

More » North American Nuclear Medicine / Radiopharmaceutical Market is Poised to Grow

North American Nuclear Medicine Market / Radiopharmaceutical Therapy Market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future.(PRWEB) April 25, 2013 The "North American Nuclear Medicine/Radiopharmaceuticals ... [Published Yahoo! News - Apr 25 2013]

Entities: radiopharmaceutical, Radioisotope, Nuclear Medicine

First reported Apr 19 2013 - Updated Apr 20 2013 - 2 reports

Report Published: "Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Global Trends & Forecast to 2017"

(live-PR.com) - Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast ... [Published Live-PR.com - Apr 20 2013]

Entities: radiopharmaceutical, Isotopes, Market, Radioisotope

First reported Apr 10 2013 - Updated Apr 10 2013 - 1 reports

European Radioisotopes Medicine Industry Analysis and Forecasts to 2017 in New Research Report at RnRMarketResearch.com

RnRMarketResearch.com adds Latest Report on “European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes ... [Published PRWeb - Apr 10 2013]

Entities: Radioisotopes, radiopharmaceutical, Radioisotope, Isotope

First reported Apr 04 2013 - Updated Apr 04 2013 - 1 reports

Analysis of Radiopharmaceuticals Market / Nuclear Medicine Industry in New Research Report at ReportsnReprots.com

“Nuclear Medicine / Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017” ... [Published PRWeb - Apr 04 2013]

Entities: radiopharmaceutical, Radioisotope, Isotope, Nuclear Medicine

First reported Feb 18 2013 - Updated Feb 18 2013 - 1 reports

More positive Alpharadin data as AlgetaBayer gear up for approval

Home » Syndicated Content » More positive Alpharadin data as Algeta/Bayer gear up for approvalRelated Biotechnology, Pharmaceutical and Healthcare NewsAs they await US and European approval for Alpharadin (radium-223) for the treatment of patients with ... [Published BioPortfolio - Feb 18 2013]

Entities: Alpharadin, Algeta ASA, Bayer AG, Biotechnology

First reported Dec 14 2012 - Updated Dec 15 2012 - 1 reports

Bayer submits prostate cancer drug for European approval

Bayer submitted an application to the European Medicines Agency seeking approval to market Alpharadin, developed by Algeta, a -More- Original Article ... [Published BioPortfolio - Dec 14 2012]

Entities: Bayer AG, antineoplastic, Prostate Cancer

First reported Dec 13 2012 - Updated Dec 13 2012 - 1 reports

Bayer files prostate cancer drug Alpharadin in the EU

German drug major Bayer (BAYN: DE) has filed for approval of its radiotherapeutic product Alpharadin for prostate cancer in Europe, triggering a 50 million euro ($65 million) milestone payment to the drug's Norwegian originator Algeta (OSE: ALGETA) Original ... [Published BioPortfolio - Dec 13 2012]

Entities: Alpharadin, Bayer AG, Prostate Cancer, antineoplastic

Quotes

"Xofigo has demonstrated an antitumor effect on bone metastases and will be an important addition to the treatment of this cancer" Oliver Sartor, M DD medicalmedical director of the Tulane Cancer Center and North American Principal Investigator for the Phase III ALSYMPCA (ALpharadin...

Bayer Prostate Cancer Drug Gains FDA Approval [Published Genetic Engineering News - May 16 2013]

More From BioPortfolio on "Fast FDA approval for Bayer's new drug for advanced prostate cancer, Xofigo"

Fast FDA approval for Bayer's new drug for advanced prostate cancer Xofigo [Published BioPortfolio - May 16 2013]

Andrew Kay, Algeta's President & CEO, said: "We are delighted that the FDA has taken the decision to approve Xofigo so quickly. We are extremely pleased to be able to make this alpha particle-emitting pharmaceutical available to US patients with castration-resistant prostate cancer and symptomatic bone metastases. We will now finalize our launch preparations for Xofigo in the US, with the intention of launching it, with Bayer, as soon as possible. This approval is a major milestone for Algeta and puts us firmly on the path to deliver on our vision to be a world-class oncology company bringing novel targeted medicines to cancer patients through our leadership in alpha particle-emitting pharmaceuticals."

Algeta ASA : Algeta announces that Xofigo® (radium-223 ... [Published Investegate - May 15 2013]

...Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's CenterCenter for Drug Evaluation and Research. "Xofigo is the second prostate cancercancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer."

FDA OKs pinpoint prostate cancer radiation drug Xofigo from Bayer, Algeta [Published FierceBiotech - May 15 2013]

More Content

sort by: Date \| Relevance
Targeted Radioisotope Therapy Extends Life for ... [Published MolecularImaging.net - May 21 2013]
Bayer's Xofigo receives US FDA approval for pro... [Published PharmaBiz - May 17 2013]
Bayer’s Xofigo wins FDA approval for treatment ... [Published Drugtopics.com - May 17 2013]
Bayer's Xofigo Cleared in the US Zacks [Published Yahoo! Finance - May 16 2013]
Bayer Prostate Cancer Drug Gains FDA Approval [Published Genetic Engineering News - May 16 2013]
FDA clears Bayer/ Algeta's prostate cancer radi... [Published PMLive - May 16 2013]
Fast FDA approval for Bayer's new drug for adva... [Published BioPortfolio - May 16 2013]
Bayer Receives U.S. FDA Approval for Cancer Tre... [Published Bayer Schering Pharma - May 15 2013]
Bayer's radiotherapy Xofigo wins FDA nod in pro... [Published FiercePharma - May 15 2013]
United States FDA Approves Algeta ASA's Xofigo [Published Reuters - May 15 2013]
Algeta ASA : Algeta announces that Xofigo® (rad... [Published Investegate - May 15 2013]
FDA OKs pinpoint prostate cancer radiation drug... [Published FierceBiotech - May 15 2013]
Dendreon Gets Prostate Cancer Competition for P... [Published 24/7 Wall St - May 15 2013]
Nuclear Medicine/Radiopharmaceuticals Market - ... [Published Individual.com - May 08 2013]
Market Research Report – Global Radiopharmaceut... [Published MarketResearch.com - May 04 2013]
Recent Study: North American Nuclear Medicine/R... [Published Live-PR.com - May 02 2013]
More » North American Nuclear Medicine / Radiop... [Published Yahoo! News - Apr 25 2013]
More » European Nuclear Medicine / Radiopharmac... [Published Yahoo! News - Apr 23 2013]
North America radiopharmaceuticals market: $2.7... [Published MyNewsDesk - Apr 23 2013]
Nuclear Medicine / Radiopharmaceutical Market i... [Published ListFree.Org - Apr 22 2013]
Report Published: "Nuclear Medicine/Radiopharma... [Published Live-PR.com - Apr 20 2013]
North American Nuclear Medicine/Radiopharmaceut... [Published PredictWallStreet - Apr 19 2013]
Report Published: "Bone Cancer - Pipeline Revie... [Published Live-PR.com - Apr 19 2013]
European radiopharmaceuticals market led by Ger... [Published Presscontacts.com - Apr 16 2013]
European radiopharmaceuticals market led by Ger... [Published MyNewsDesk - Apr 16 2013]
European Radioisotopes Medicine Industry Analys... [Published PRWeb - Apr 10 2013]
Analysis of Radiopharmaceuticals Market / Nucle... [Published PRWeb - Apr 04 2013]
Research and Markets: Alpharadin (Prostate Canc... [Published Business Wire Health News - Mar 15 2013]
More positive Alpharadin data as AlgetaBayer ge... [Published BioPortfolio - Feb 18 2013]
Deals Of The Week Notes Bayer's Partnerships Ar... [Published The IN VIVO Blog - Feb 15 2013]